Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) is expected to be selected for part of the national drug procurement program.

Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced that its fully owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd. (referred to as "Borui Pharmaceutical"), recently participated in the national organization's centralized procurement of drugs for the expiration of the agreement period for continued procurement of drugs. According to the announcement of the results of the selection for the continuation procurement of drugs for the expiration of the agreement period organized by the procurement office on February 10, 2026, the company's products including Aganirsen Injection were selected for this procurement. The four products selected by the company in this procurement had a total sales revenue of 88,847,500 RMB during the first three quarters of 2025, accounting for 10.16% of the company's total revenue during the same period. During the procurement period, medical institutions will prioritize the use of the selected drugs from this procurement and ensure the completion of the agreed purchasing quantity. If subsequent procurement contracts are signed and implemented, it will further increase the sales volume of the products, improve market share, and enhance the company's brand image.